Potential Anticancer Effects of Limonene Associated with Reactive Oxygen Species Generation, Apoptosis Induction, and NF-κB Modulation in Papillary Renal Cell Carcinoma: A Preliminary Study Authors: Mahshad Ghanbari, Roham Deyhimfar, Fatemeh Khatami, Idris Haghani, Iman Menbari Oskouie, Mahdi Khoshchehreh, Seyed Mohammad Kazem Aghamir Published: 2026 ABSTRACT AbstractBackgroundTumor recurrence and progression occur in many patients with renal cell carcinoma, highlighting a clinical demand for safe and effective treatment options, particularly by employing plant-derived bioactive compounds. Limonene, an aromatic monoterpene commonly found in citrus peels, has been shown to possess anticancer effects in malignancies such as prostate and bladder cancers.ObjectivesThis study aimed to explore the potential anticancer effects of limonene on ACHN papillary renal cancer cells (pRCC).MethodsThe viability of ACHN, human embryonic kidney (HEK293), and human dermal fibroblast (HDF) cells treated with limonene was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Cellular migration, colony formation, 3D spheroid development, morphological alterations, and caspase 3/7 activity were evaluated in vitro. Reactive oxygen species (ROS) levels, apoptosis, and cell cycle alterations were analyzed by flow cytometry. The mRNA levels of BAX, BCL2, E-cadherin, N-cadherin, Caspase-3, Caspase-9, NF-κB, Akt1, MMP-2, MMP-9, mTOR, TNF-α, COX-2, and IL-6 were quantified using quantitative polymerase chain reaction. NF-κB protein levels and IκB phosphorylation were assessed by Western blot. Nuclear NF-κB levels were measured by ELISA.ResultsThe viability of ACHN cells was reduced by limonene in a dose- and time-dependent manner, with comparatively limited effects on HEK293 and HDF cells. Limonene significantly reduced migration, colony formation, and spheroid growth in ACHN cells. Furthermore, limonene elevated ROS levels and increased apoptosis in ACHN cells without affecting cell cycle progression. After limonene exposure, mRNA expression of Akt1, mTOR, NF-κB, MMP-2, N-cadherin, BCL2, TNF-α, COX-2, and IL-6 decreased, whereas BAX and E-cadherin expression increased. Caspase-3 and Caspase-9 mRNA levels were not significantly altered, whereas caspase 3/7 activity increased. Limonene also reduced NF-κB protein levels, IκB phosphorylation, and NF-κB nuclear translocation.ConclusionsThese preliminary in vitro findings support further investigation of limonene as a therapeutic candidate in additional pRCC models.Keywords: renal cell carcinoma, limonene, reactive oxygen species, apoptosis, ACHN, NF-κB Introduction Kidney cancer is the 14th most common cancer worldwide, with 434,840 newly diagnosed cases in 2022, and also the 10th and 13th highest incidence rates among men and women, respectively [1,2]. Renal cell carcinoma (RCC), the most common type of kidney malignancy, is categorized into 3 major subtypes: clear-cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC [3,4]. pRCC is the second most common subtype of RCC, representing 15% to 20% of RCC cases [5], with the majority of patients presenting localized tumors and surgical intervention, either radical or partial nephrectomy, remains the best treatment approach [5]. The 2 most common complications of partial nephrectomy are bleeding during or after surgery and urinary fistula; however, 5% to 10% of patients experience pedicle injury or damage to adjacent organs [6]. Other treatment options for pRCC include cryoablation, radiofrequency ablation, and microwave ablation [7]. After surgery, 20% to 40% of patients experience disease progression or recurrence [8]. Upon disease recurrence, patients often undergo treatments such as cytokine therapy, targeted therapy, and immunotherapy with immune checkpoint inhibitors (ICIs), which can be largely ineffective. Despite the promising outcomes of these therapies, resistance and disease progression remain a common challenge for many patients [9]. Immunotherapies used for RCC include ICIs, vaccines, adaptive T-cell therapies, and T-cell agonists and agonistic antibodies [10,11]. Also, ICIs and vascular endothelial growth factor receptor (VEGFR) inhibitors are commonly used treatments for patients with pRCC [5]. Although immunotherapy shows promise in RCC, side effects in immunocompromised patients, along with therapeutic resistance and dysfunctional dendritic cells, cannot be overlooked [9]. Furthermore, evidence suggests that although pRCC and ccRCC receive similar treatment approaches, both type 1 and type 2 pRCC exhibit limited therapeutic response [12]. Therefore, developing new and safe treatments, particularly those derived from natural compounds, is essential [9]. Limonene is a monoterpene that naturally occurs in citrus fruits and various vegetables. This bioactive compound has demonstrated promising potential for clinical use as an antimicrobial and antifungal agent [13,14]. Evidence supports limonene’s anticancer effects across multiple cancers, including colon [15], lung [16], neuroblastoma [17], prostate [18], and bladder [19]. In several cancer models, limonene influences apoptotic pathways by activating caspases 3, 7, and 9, raising Bax and Bak expression, and reducing BCL2 and BCL-x gene expression [20]. Moreover, limonene has been found to inhibit mTOR signaling [21] while simultaneously inhibiting the Akt/PI3K pathway [22]. In addition, D-limonene increased the efficacy of docetaxel chemotherapy by enhancing oxidative stress in cancer cells [18]. Recent studies have demonstrated that dysregulation and overexpression of the NF-κB and mTOR pathways can contribute to the development of RCC [23,24]. Enhanced mTOR/PI3K/Akt signaling, involved in multiple cellular activities including anabolic metabolism, autophagy, and angiogenesis, together with phosphatase and tensin homolog (PTEN) inhibition, leads to tumor growth, migration, and metastasis in RCC [24]. Several gene mutations, particularly in the MET receptor initially identified in pRCC, alter NF-κB expression patterns and contribute prominently to pRCC development by affecting the tyrosine kinase domain and triggering oncogenic signaling. In patients with ccRCC, NF-κB continuously promotes resistance to therapy. Furthermore, it has been observed that upregulated NF-κB correlates with drug resistance to metformin, sorafenib, and gefitinib, whereas downregulated NF-κB is associated with drug sensitivity [23]. Although the therapeutic benefits of limonene have been studied in various cancers, its impact on pRCC remains unexplored. This study aims to investigate the anticancer activity of limonene against the ACHN cell line in vitro. Methods Cell culture and reagents Human papillary renal carcinoma cell line (ACHN), human embryonic kidney cells (HEK293), and human dermal fibroblast (HDF) cells were obtained from Pasteur Institute of Iran and cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco, LOT number: 2496281) with 10% of heat-inactivated fetal bovine serum (Gibco, LOT number: 2749486), 100 units/mL of penicillin and 100 μg/mL of streptomycin at the temperature of 37°C, 95% humidity, and carbon dioxide levels of 5%. All cell lines were maintained at passage numbers below 10 during the experiments. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) cell viability assay kit (CAT number: DMA500) and phosphate buffered saline (PBS, CAT number: DB0010) were obtained from DNA Biotech. Limonene (Sigma-Aldrich, CAS number: 5989-27-5) was dissolved in 100% dimethyl sulfoxide (DMSO, Sigma-Aldrich, CAS number: 67-68-5). The final solution included 1% DMSO (v/v) in the culture medium. A similar concentration of DMSO (1%, v/v) was employed as the control group. Cytotoxicity evaluation using MTT The dose-response of limonene against ACHN, HEK293, and HDF cells was assessed by MTT assay. 1.0 × 104 cells were cultured in each well of a 96-well plate. Cells were then treated with 0, 150, 300, 450, 600, and 750 μM concentrations of limonene for 24, 48, and 72 h. In total, 100 μL of MTT solution (0.5 mg/mL in PBS) was added to each of the wells. After 4 h of incubation at 37°C, the dye-containing medium was discarded, and DMSO was added to each well to dissolve formazan crystals. The absorbance was measured using a microplate reader (Hiperion) at 545 nm. The half-maximal inhibitory concentration (IC50) of limonene was calculated using the IC50 Calculator web tool offered by AAT Bioquest [25]. The percent of cellular viability was calculated using the following formula: Cell morphology ACHN cells were seeded at a density of 1.0 × 104 cells in each well of a 24-well plate. After reaching 80% confluency, cells were treated with 350 and 550 μM limonene for 24 h, then washed with PBS. Cells were fixed with 4% (v/v) paraformaldehyde solution for 15 min, then stained with 0.2% crystal violet. After 20 min, the stains were washed, and the samples were examined under an inverted microscope (Optika, Italy) at 100× magnification. Migration assessment by wound-scratch assay ACHN cells were seeded at a density of 2.5 × 104 cells in each well of a 24-well plate and were incubated until reaching 90% confluence. Thereafter, the DMEM medium was removed, and the cells were washed twice with PBS. A vertical wound was created in each well using a 100 μL micropipette tip, and then cells were treated with limonene (0, 350, and 550 μM). Cells were incubated at 37°C for 24 h. Photographs of the scratch area were taken at 0 and 24 h under the 100× magnification and analyzed using ImageJ software (Wayne Rasband, NIH, 1.52v). The wound closure rate was determined by the following equation: Colony-forming assay ACHN cells were seeded in 6-well plates at a density of 1.0 × 102 cells per well and then were treated with limonene (0, 350, and 550 μM) for 24 h. The medium was changed every 72 h for 8 d. Afterward, colonies were fixed with 4% (v/v) paraformaldehyde for a total of 20 min and stained with 0.2% (w/v) crystal violet. Colonies were photographed and analyzed using ImageJ software (1.52v). Spheroid formation assay A density of 5.0 × 103 ACHN cells was seeded in each well of 1% agarose-coated 96-well plates. After 72 h, spheroids were treated with limonene (0, 350, and 550 μM) for 24 h. After treatment, spheroids were examined under an inverted light microscope (Optika) at 100× magnification, and their diameters were measured using ImageJ software (1.52v). Spheroid volumes were calculated according to the following formula: Reactive oxygen species measurement Intracellular reactive oxygen species (ROS) levels were measured using 2,7-dichlorodihydrofluorescein diacetate (DCFDA; Kiazist) according to the manufacturer’s instructions. Briefly, ACHN cells were seeded at a density of 3.0 × 105 cells per well in a 6-well plate. After reaching 80% confluency, cells were treated with 550 μM limonene for 24 h. After treatment, cells were washed twice with ROS buffer and then incubated with 20 μM DCFDA working solution for 45 min in the dark at 37°C. Fluorescence was measured at 490/530 nm (excitation/emission) using a flow cytometer (BD FACSCalibur). Data were analyzed by the FlowJo software (Waters Biosciences, V8/9). Flow cytometric analysis of viability, apoptosis, and necrosis ACHN cells were seeded at a density of 3 × 105 cells per well in a 6-well plate until 80% confluency. Then, cells were treated with limonene (0 and 550 μM) for 24 h. Viability, apoptosis, and necrosis were measured using a Fluorescein-conjugated annexin V (annexin V-FITC) staining kit (CAT number: 640914) according to the manufacturer’s protocols. Annexin V and propidium iodide (PI) solution were applied to cells, followed by a 15-min incubation at room temperature in darkness. Fluorescence signals were quantified using flow cytometry (BD). All data were analyzed using FlowJo software (v9.6.3). Caspase 3/7 activity assay ACHN cells were seeded at a density of 3.0 × 105 cells per well in a 6-well plate. After reaching 80% confluency, cells were treated with 550 μM limonene for 24 h. Caspase 3/7 activity was determined using a DEVD-pNA colorimetric assay kit (Kiazist) according to the manufacturer’s instructions. The amount of released pNA moiety after 120 min, which correlates directly with caspase 3/7 activities, was measured at 405 nm using a microplate reader (Hiperion). All caspase activities were normalized to the total protein of the samples, measured by the bicinchoninic acid (BCA, DNAbiotech) technique according to the manufacturer’s protocol. Flow cytometric analysis of cell cycle progression ACHN cells were seeded at a density of 3 × 105 cells in each well of a 6-well plate until achieving 80% confluence. Then, cells were treated with limonene (0 and 550 μM) for 24 h. After incubation, cells were fixed in 70% ethanol at −20°C for 24 h and subsequently washed with PBS. Afterward, cells were incubated with RNase A at 100 μg/mL and subsequently stained with 500 μL of a PI solution prepared at 50 μg/mL in a mixture of 0.1% Triton X-100 and 0.1% sodium citrate for 30 min at 37°C. For DNA content assessment, a BD flow cytometer was used, and the data were analyzed with FlowJo software version 9.6.3. Quantitative data (% of cells per phase) of cell cycle distribution are provided in Supplementary Table 1. RNA extraction, cDNA synthesis, and gene expression estimation by qPCR ACHN cells were seeded at a density of 3 × 105 cells per well in a 6-well plate until 80% confluency. Then, cells were treated with limonene (0 and 550 μM) for 24 h. Total RNA isolation was performed with RiboEx reagent (CAT number: A325402; Batch number: 21k1501) according to the previously described protocol [26]. Briefly, cells were homogenized with the RiboEx reagent, and chloroform was added for phase separation, and the mixture was centrifuged to isolate the aqueous layer. RNA precipitation was achieved using isopropanol, followed by ethanol washes for purification. RNA quality and yield were assessed by spectrophotometric measurement (Nanodrop ND-1000, Nanodrop Technologies) via absorbance at 260 and 280 nm. For cDNA synthesis, ∼3 μg of total RNA underwent reverse transcription with the PrimeScript RT reagent kit (Pars Toos. Co; LOT number: CS0050). Target genes (BAX, BCL2, E-cadherin, N-cadherin, Caspase-3, Caspase-9, NF-κB, Akt1, MMP-2, MMP-9, mTOR, TNF-α, COX-2, and IL-6) were quantified using a Step OnePlus real-time PCR instrument (Thermo Fisher Scientific). Each cycle consisted of a denaturation step at 95°C for 60 s, a primer annealing step at 60°C for 30 s, and an elongation step at 72°C for 40 s, using SYBR Green Master Mix (Ampliqon). Amplification data were normalized to the endogenous control β-actin, and relative gene expression was computed via the 2-ΔΔCT method. Primer sequences are listed in Table 1. TABLE 1Nucleotide sequence of specific primers used in qPCRTABLE 1Target mRNAForward primer (5′→3′)Reverse primer (5′→3′)Akt1GGTTGGCTGCACAAACGAGGTGCCGCTCCGTCTTCATCAGB-ActinAGAGCCTCGCCTTTGCCGATCTGACCCATGCCCACCATCABAXTGGAGCTGCAGAGGATGATTGGAAGTTGCCGTCAGAAAACATGBCL2CAGCTATAACTGGAGAGTGCCCACTTCCTCTGTGATGTTGTACaspase-3GATCGTTGTAGAAGTCTAACTGGGGCATACTGTTTCAGCATGGCaspase-9GCTGGACGCCATATCTAGTTTGGTCTCAACGTACCAGGAGCE-cadherinTCGTAACGACGTTGCACCAATTCGGAACCGCTTCCTTCATMMP-2ATAACCTGGATGCCGTCGTGAGCCTAGCCAGTCGGATTTGMMP-9CGGTTTGGAAACGCAGATGGTCCTGGGTGTAGAGTCTCTCGmTORAGGACGACCCAGAGCTGATGGCTGTCCCACTGACCTAAACN-cadherinGCCATCAAGCCTGTGGGAATGGAGCCACTGCCTTCATAGTNF-κBGAAAATGGTGGAGTCTGGGAAGGTCAGATTTCCTCCGAAGCTGTNF-αGCCTCTTCTCCTTCCTGATCGCAGCTTGAGGGTTTGCTACAACCOX-2AAATTGCTGGCAGGGTTGCTGCAGACATTTCCTTTTCTCCTGIL-6CACTGGTCTTTTGGAGTTTGAGGGTCAGGGGTGGTTATTGCATC Nucleotide sequence of specific primers used in qPCR Western blotting Cells were placed on ice, washed twice with ice-cold PBS, and lysed using radioimmunoprecipitation assaybuffer supplemented with protease and phosphatase inhibitors. Lysates were then centrifuged at 15,000 × g at 4°C for 12 min to remove cell debris. The protein content of each supernatant was determined using a Bradford assay, and 15 μg of protein was loaded into each well. Samples were separated using 10% SDS-PAGE and transferred onto polyvinylidene fluoride membranes. Membranes were blocked in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and 5% nonfat dry milk for 1 h at room temperature, before incubation with primary antibodies at recommended dilutions overnight at 4°C. The membranes were then washed with TBS-T and incubated with horseradish peroxidase–conjugated secondary antibodies for 1 h at room temperature. The membranes were visualized on X-ray film using the enhanced chemiluminescence detection system (Sigma-Aldrich). Band intensities were quantified using ImageJ and normalized to β-actin. The primary and secondary antibodies used are listed in Table 2. The original, uncropped blots are provided in Supplementary Figures 1 to 4. TABLE 2Primary and secondary antibodies used in Western blottingTABLE 2AntibodiesSourceCatalog numberAntihuman NF-κB p65 monoclonal antibodySanta Cruz Biotechnologysc-8008Antihuman p-IκB-α monoclonal antibodySanta Cruz Biotechnologysc-8404Antihuman β-Actin monoclonal antibodySanta Cruz Biotechnologysc-517582IgGκ light chain binding protein (HRP-conjugated)Santa Cruz Biotechnologysc-516102Abbreviation: HRP, horseradish peroxidase. Primary and secondary antibodies used in Western blotting Abbreviation: HRP, horseradish peroxidase. Subcellular fractionation and ELISA ACHN cells were seeded at a density of 3 × 105 cells per well in 6-well plates and incubated until reaching 80% confluency. The cells were then treated with limonene (0 and 550 μM) for 24 h. For nuclear fraction isolation, cells were washed with PBS, trypsinized, and centrifuged at 300 × g for 5 min at 4°C. The cell pellet was resuspended in 2 mL of hypotonic buffer (10 mM Tris, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 0.5% Triton X-100) and incubated on ice for 15 min. The cells were then homogenized by pulse-vortexing and centrifuged at 700 × g for 10 min at 4°C. The resulting nuclear pellet was resuspended in PBS and centrifuged at 500 × g for 2 min. The pellet was resuspended in PBS and centrifuged again at 300 × g for 2 min. The nuclear pellet was subsequently lysed using radioimmunoprecipitation assay buffercontaining protease and phosphatase inhibitors. The resulting lysates were centrifuged at 15,000 × g for 12 min at 4°C. Equal volumes of lysates were subjected to ELISA to quantify GAPDH (Thermo Fisher Scientific; Cat. No. EH207RB), Lamin B1 (Abcam; Cat. No. ab252351), and NF-κB (Abcam; Cat. No. ab176648), according to the manufacturers’ instructions. The data were normalized to the total protein concentration determined by the BCA assay. Statistical analysis Data are presented as the mean ± SD. All experiments were performed in biological triplicates, and statistical significance between 2 groups was assessed using an unpaired Student’s t-test in GraphPad Prism 10 (GraphPad Software). One-way analysis of variance with Dunnett as post hoc analysis was conducted for multigroup comparisons. P values < 0.05 were considered statistically significant. Results Limonene induced cytotoxicity and morphological alterations in ACHN cells First, the cytotoxicity of limonene on ACHN cells was assessed using an MTT assay. The results suggested that limonene decreased ACHN cell viability in a time- and dose-dependent manner. The estimated 24-h IC50 of limonene in ACHN cells was ∼550 μM (Figure 1A). After 24 h of limonene treatment, HEK293 and HDF cell viability showed no significant change and was substantially higher than ACHN cell viability at 48 and 72 h (Figure 1B, C). Limonene treatment for 24 h at concentrations of 350 μM (viability: 71.3%) and 550 μM (viability: 50.2%) was selected for subsequent analysis in ACHN cells. Additionally, ACHN cells underwent morphological alterations, including rounding and shrinkage, after exposure to limonene for 24 h in a dose-dependent manner (Figure 1D). Limonene induced cytotoxicity and morphological alteration in ACHN cells. (A–C) ACHN, HEK293, and HDF cells treated with limonene were examined for cell viability using the MTT assay (n = 3). Data are reported as mean ± SD. (D) The morphological features of ACHN cells in the control and limonene-treated groups. Scale bars represent 100 μm. For each biological replicate, images were randomly acquired from 3 independent microscopic fields. One-way analysis of variance with post hoc analysis (Dunnett) was performed to compare multiple groups. Statistical significance for all comparisons was determined compared with the control group, represented by the asterisk. P value <0.05 is regarded as statistically significant (∗∗∗∗P < 0.0001, ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05). ns, not significant. Limonene does not alter cell cycle progression but suppresses the colony formation, 3D growth, and migration of ACHN cells Cell cycle analysis showed no significant change in cycle phases between the control and limonene-treated groups (P > 0.05; Figure 2A). Additionally, 24 h of incubation with 350 and 550 μM limonene resulted in 77.9% and 96.7% reductions in colony number in the treated groups compared with the control group (P < 0.05, Figure 2B). To investigate limonene’s effect on 3D growth of ACHN cells, a spheroid formation assay was performed. At concentrations of 350 μM and 550 μM, this natural compound reduced spheroid volumes by 29.4% and 36.9%, respectively (P < 0.01; Figure 2C). To evaluate whether limonene inhibits cell migration, the wound-healing assay was performed. Because conducting this assay with limonene at the IC50 value was not feasible because of the remarkable cell detachment, ACHN cells were treated exclusively with 350 μM limonene. Results indicated that limonene significantly inhibited the migratory potential of ACHN cells by 85.2% even at a sub-IC50 concentration (P < 0.0001; Figure 3A). Moreover, limonene upregulated the mRNA expression of E-cadherin by 2.8-fold and downregulated the mRNA expression of N-cadherin, MMP-2, and MMP-9 by 81.6%, 61.9%, and 83.2% in ACHN cells, respectively (P < 0.01; Figure 3B). Limonene does not alter cell cycle progression but suppresses the colony formation and 3D growth of ACHN cells. (A) Analysis of cell cycle distribution through flow cytometry in ACHN cells (n = 3). Quantitative data (% of cells per phase) of cell cycle distribution are provided in Supplemental Table 1. (B) Colony formation assay of ACHN cells after treatment with 350 and 550 μM of limonene (n = 3). The colony number was evaluated utilizing ImageJ software. (C) Spheroid growth assay to assess 3D growth of ACHN cells after treating with limonene (n = 3). Scale bars represent 100 μm. Data are reported as mean ± SD. Statistical significance for all comparisons was determined compared with the control group, represented by the asterisk. P value <0.05 is regarded as statistically significant (∗∗∗∗P < 0.0001, ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05). ns, not significant. Limonene modulated migration and EMT-related gene expression of ACHN cells. (A) Assessment of migratory potential of ACHN cells after treatment with limonene using wound-healing assay (n = 3). Photos of the scratch were taken from 3 fields before treating with 350 μM limonene and 24 h after treatment. Scale bars are 100 μm. (B) Evaluating the impact of limonene on mRNA expression of EMT-related genes E-cadherin, N-cadherin, MMP-2, and MMP-9 in ACHN cells. β-Actin served as the internal control. Data are reported as mean ± SD. Statistical significance for all comparisons was determined compared with the control group, represented by the asterisk. P value <0.05 is regarded as statistically significant (∗∗∗∗P < 0.0001, ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05). EMT, epithelial-mesenchymal transition; ns, not significant. Limonene elevates intracellular ROS levels and promotes apoptosis in ACHN cells ACHN cells in the control or limonene-treated groups were cultured for 24 h and then analyzed by flow cytometry to evaluate intracellular ROS levels, viability, apoptosis, and necrosis. Results demonstrated that limonene significantly increased the ROS levels by 45.8% after 24 h (P < 0.05; Figure 4A). Additionally, the apoptosis rate in the treated group increased from 3.52% to 18.83% compared with the control group (P < 0.01; Figure 4B). qPCR analysis showed that BAX mRNA levels increased by 6-fold and BCL2 mRNA levels decreased by 78.3% after 24 h of limonene treatment (P < 0.01). The mRNA levels of Caspase-3 and Caspase-9 did not change significantly after limonene treatment (P > 0.05; Figure 4C). However, limonene significantly increased caspase 3/7 activity in ACHN cells by 42.71% compared with the control group (P < 0.001; Figure 4D). Limonene elevates intracellular ROS levels and promotes apoptosis in ACHN cells. (A) Evaluation of intracellular ROS induction in ACHN cells by flow cytometry (n = 3). (B) Evaluation of viability, apoptosis, and necrosis in ACHN cells after limonene treatment by flow cytometry (n = 3). Each scatter plot is divided into 4 quadrants: viable cells in the lower left, early apoptotic cells in the lower right, late apoptotic cells in the upper right, and necrotic cells in the upper left. (C) Evaluating the influence of limonene on mRNA expression of BAX, BCL2, Caspase-3, and Caspase-9 in ACHN cells (n = 3). β-Actin served as the internal control. (D) Measurement of Caspase 3/7 activity in ACHN cells after limonene treatment (n = 3). Caspase activity was normalized to the total protein concentration of the experimental groups. Data are reported as mean ± SD. Statistical significance for all comparisons was determined compared with the control group, represented by the asterisk. P value <0.05 is regarded as statistically significant (∗∗∗∗P < 0.0001, ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05). ROS, reactive oxygen species; ns, not significant. Limonene downregulates Akt, mTOR, and NF-κB expression and inhibits IκB phosphorylation in ACHN cells After 24 h of limonene exposure, the expression of Akt, mTOR, and NF-κB was measured by real-time PCR in ACHN cells. Our results showed a 47.7% reduction in Akt1, 36% in mTOR, and 73.9% in NF-κB mRNA levels compared with the control group (P < 0.05; Figure 5A). Because NF-κB mRNA was mostly affected by limonene in ACHN cells, its protein expression was further evaluated by Western blotting. The results showed that limonene reduced NF-κB protein levels by ∼16% (P < 0.001; Figure 5B, C). Additionally, phosphorylation of IκB, a classical inhibitor of NF-κB translocation, was examined and found to decrease by 54.7% after limonene treatment (P < 0.001; Figure 5B, C). Nuclear translocation analysis further revealed a 35.2% reduction in nuclear NF-κB levels (P < 0.0001; Figure 5D). The transcriptional activity of NF-κB was also evaluated by examining the expression of its downstream target genes, including MMP-9, BCL2, TNF-α, COX-2, and IL-6 [[27], [28], [29], [30], [31]]. The results demonstrated that limonene significantly reduced MMP-9, BCL2, TNF-α, COX-2, and IL-6 mRNA levels compared with the control group (P < 0.05; Figure 5E). Limonene downregulates Akt, mTOR, and NF-κB expression and inhibits IκB phosphorylation in ACHN cells. (A) Evaluating the impact of limonene on mRNA expression of Akt1, mTOR, and NF-κB in ACHN cells. β-Actin served as the internal control (n = 3). (B, C) Western blot analysis to assess the protein levels of NF-κB, IκB-p, and β-Actin in ACHN cells (n = 3). The original, uncropped blots are provided in Supplemental Figures 1–4. (D) ELISA-based quantification of nuclear NF-κB expression in ACHN cells after limonene treatment (n = 3). GAPDH and Lamin B1 levels were also evaluated to confirm the presence of nuclear fraction and the absence of cytoplasmic contamination. (E) Evaluating the impact of limonene on mRNA expression of NF-κB downstream target genes MMP-9, BCL2, TNF-α, COX-2, and IL-6 in ACHN cells (n = 3). Data are reported as mean ± SD. Statistical significance for all comparisons was determined compared with the control group, represented by the asterisk. P value <0.05 is regarded as statistically significant (∗∗∗∗P < 0.0001, ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05). ns, not significant. Discussion Over 400,000 individuals were diagnosed with kidney cancer in 2022, particularly RCC [2]. Although surgical intervention is standard for localized RCC, 40% of those treated surgically suffer from relapse [32]. Limonene is an aromatic monoterpene predominantly found in citrus fruits [33]. Studies have shown that limonene exerts antitumor [34] effects by inhibiting angiogenesis, inducing apoptosis, and modulating signaling pathways, including PI3K/Akt, JNK/p38, and Raf/MEK/ERK [20]. To our knowledge, this is the first study to explore the anticancer effects of limonene on pRCC cells, showing that it elevates intracellular ROS, promotes apoptosis, and modulates epithelial-mesenchymal transition (EMT)–associated gene expression, migration, colony-forming ability, and spheroid development, along with modulating Akt, mTOR, and NF-κB expression in ACHN cells. Metastasis remains a major clinical challenge in RCC, with 20% to 30% of patients diagnosed at an early stage and 30% to 50% eventually developing metastatic disease in organs such as the lungs, bones, brain, and others [35]. Ye et al. [19] demonstrated that limonene inhibits the migration and invasion of human bladder cancer cells, as shown by wound-healing and transwell assays, indicating its potential to suppress metastasis. Tumor cells primarily produce matrix metalloproteinases (MMPs), zinc-associated proteases with a confirmed role in driving tumor invasion and metastasis [36]. The study by Rani et al. [37] demonstrated that limonene-loaded liposomes decreased MMP-2 and MMP-9 levels in glioma cancer cells. Our findings revealed a significant reduction in MMP-2 and MMP-9 expression. In addition, our findings demonstrated significantly elevated E-cadherin expression accompanied by reduced N-cadherin expression. Taken together, these data indicate that limonene effectively attenuates EMT and cell migration in ACHN cells. Previous studies have shown that limonene can induce ROS production in cancer cells, thereby promoting apoptosis. Petretto et al. [38] reported that limonene treatment increased ROS levels and reduced HeLa cell viability in a dose-dependent manner. Similarly, Rabi and Bishayee [18] found that limonene enhanced docetaxel-induced ROS generation and subsequent apoptosis in prostate cancer cells. Consistent with previous reports, limonene significantly increased intracellular ROS in ACHN cells, along with upregulation of BAX and downregulation of BCL2, indicating a potential role for mitochondrial-dependent apoptosis. According to Salim et al. [39], limonene plays a significant role in inducing apoptosis in breast and liver cancer cells. They further showed a significant increase in BAX expression and a decrease in BCL2 expression. Consistent with earlier research, we found that limonene promotes apoptosis by increasing BAX expression and decreasing BCL2 levels. The research by Zhang et al. [40] demonstrated that the synergy of berberine and limonene elevates Caspase-3 in human gastric carcinoma cells. Rabi and Bishayee [18] demonstrated that limonene induces cleavage of both Caspase-3 and Caspase-9, enhancing docetaxel’s cytotoxicity in prostate cancer cells. Surprisingly, our data revealed no significant changes in Caspase-3 and Caspase-9 levels in ACHN cells after 24 h of limonene treatment. However, additional analyses revealed that limonene treatment was associated with elevated caspase 3/7 activity and apoptosis. These results suggest that limonene may primarily influence post-translational regulation, such as proteolytic cleavage, rather than altering mRNA expression. Future studies are warranted to elucidate the mechanisms underlying limonene-mediated post-translational activation of caspase 3 and caspase 9. Although limonene has been reported to inhibit proliferation by inducing cell cycle arrest in various cancer cells [19,37,39], our results showed no significant alteration in cell cycle phases between treated and control groups. Studies have reported that treating lung and breast cancer cells with limonene reduces the colony formation in vitro [16,41]. Our results showed a significant dose-dependent decrease in colony-forming ability in the limonene-treated group compared with the control group. Similar results were obtained from the spheroid formation assay, which aimed to recapitulate the in vivo 3D conditions of cancer cells. Because no significant difference in cell cycle analysis was observed between the treated and control groups, the reductions in spheroid and colony formation are likely due to apoptosis rather than to inhibition of cell proliferation. Future studies should focus on identifying mechanisms that may compensate for or bypass limonene’s antiproliferative activity in pRCC cells. Numerous studies have demonstrated that abnormalities in the PI3K/mTOR/Akt pathway are present in various malignancies, with confirmed effects on the survival and growth of breast, bladder, and especially renal cancers [21,24]. Earlier investigations documented that limonene can suppress the PI3K/mTOR/Akt signaling pathway [42]. Moreover, limonene-rich blood orange volatile oil has been reported to markedly downregulate Akt1 expression in several colon cancer cell lines, whereas limonene itself suppresses Akt1 phosphorylation and kinase activity [15,22]. Our results showed a significant decrease in Akt1 and mTOR expression in the limonene-treated group compared with the control group. Also, the relationship between NF-κB expression and RCC has been examined in prior research. NF-κB is a central regulator of cellular responses and has been shown to promote RCC cell survival, and NF-κB inhibition has therapeutic potential in autoimmune disorders and cancer [23]. In a rat model of coronavirus-associated pulmonary fibrosis, Yang et al. [43] found that limonene treatment significantly decreased NF-κB levels and reduced expression of downstream targets, including IL-6 and TNF-α [43]. In line with these observations, we found that limonene significantly decreased NF-κB expression at both the mRNA and protein levels compared with the control group. Notably, NF-κB mRNA decreased markedly, whereas the decline in total NF-κB protein was comparatively modest. This discrepancy may reflect high turnover dynamics or an insufficient treatment duration for transcriptional changes, warranting further studies with extended exposure times. Importantly, although total NF-κB protein levels were not markedly reduced in ACHN cells, limonene significantly decreased IκB phosphorylation, a key regulator that prevents NF-κB nuclear translocation by masking its nuclear localization signal. Furthermore, limonene treatment substantially reduced NF-κB nuclear translocation and the expression of NF-κB-responsive genes (MMP-9, BCL2, TNF-α, COX-2, and IL-6), indicating diminished NF-κB transcriptional activity in ACHN cells. Therefore, limonene primarily mediates suppression of NF-κB activation in ACHN cells rather than simply reduced total NF-κB abundance. This mechanism may be further validated in future studies using approaches such as NF-κB luciferase reporter assays, pathway rescue experiments, molecular docking, and gel shift assay. Our MTT assay results showed that limonene exhibits cytotoxicity in ACHN cells but minimal toxicity toward HEK293 and HDF cells, suggesting potential safety that warrants further validation in in vivo experiments. Because only one pRCC cell line was employed in this study, the results must be interpreted cautiously. Given that ccRCC is the most frequent RCC subtype, future studies using additional RCC cell lines, such as Caki-2 or 786-O, are recommended to better understand the anticancer effects of this monoterpene in other RCC subtypes. Furthermore, in vivo studies are essential to determine limonene’s pharmacokinetics, bioavailability, and evaluate its effects on pRCC under physiological conditions within the tumor microenvironment. Also, subsequent investigations should focus on uncovering the molecular mechanisms of limonene and related signaling pathways, such as Akt/mTOR, in RCC subtypes. In conclusion, this preliminary in vitro study shows that limonene reduces ACHN cell viability, clonogenic growth, spheroid development, and wound closure, while increasing ROS accumulation and apoptosis. Limonene treatment was also associated with reduced IκB phosphorylation, decreased nuclear NF-κB levels, and lower expression of NF-κB-responsive genes. These findings provide an early foundation for future studies to evaluate limonene’s potential as a therapeutic candidate for pRCC. Author contributions The authors’ responsibilities were as follows – MG: was responsible for methodology, investigation, formal analysis, visualization, and writing the original draft; RD: was responsible for conceptualization, methodology, investigation, supervision, and writing – review and editing; FK: was responsible for validation; IH: was responsible for investigation; IMO: was responsible for resources; MK: was responsible for validation; and SMKA: was responsible for conceptualization, project administration, funding acquisition, and resources. Data availability The data that support the findings of this study are available from corresponding upon reasonable request. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of generative AI and AI-assisted technologies in the writing process The author(s) declare that no generative AI or AI-assisted technologies were used in the writing of this manuscript. Conflict of interest The authors report no conflicts of interest. Acknowledgments We thank all personnel of Urology Research Center at Sina Hospital for their technical support. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.cdnut.2026.109392. Supplementary data The following is the Supplementary data to this article: multimedia component 1 References Associated Data Supplementary Materials multimedia component 1 Data Availability Statement The data that support the findings of this study are available from corresponding upon reasonable request.